Oncology

May 6th 2025

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.

May 5th 2025

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

May 2nd 2025

An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.

May 2nd 2025

As skin cancer rates continue to rise, here are 5 key facts every health care professional should know to improve prevention, early detection, and patient outcomes.